Method for decreasing body weight using a somatostatin receptor agonist
View Patent ↗The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.
1. A method of maintaining body weight or reducing body weight gain in an overweight patient, comprising the step of:
administering a therapeutically effective amount of a somatostatin type-5 receptor selective peptide agonist to an overweight patient;
wherein said effective amount of said somatostatin type-5 receptor selective peptide agonist results in a decrease of body weight and
wherein said somatostatin type-5 receptor selective peptide agonist has a Ki for the somatostatin type-5 receptor that is at least 2 times less than the Ki for the somatostatin type-2 receptor.
2. A method according to claim 1 wherein the somatostatin agonist is
H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH 2 ,
H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH 2 ,
H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH 2 or
H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH 2 .
3. A method according to claim 1 wherein the somatostatin agonist is
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH 2 .
4. A method according to claim 1 wherein the somatostatin agonist is
5. The method according to claim 1 , wherein said decrease of body weight is measured by assessing total body weight.
6. The method according to claim 1 , wherein said decrease of body weight is measured by assessing body mass index.
7. The method according to claim 1 , wherein said decrease of body weight is measured by assessing total adipose tissue content.
8. The method according to claim 1 , wherein said decrease of body weight is measured by assessing subcutaneous tissue content.
9. The method according to claim 1 , wherein said decrease of body weight is measured by assessing visceral adipose tissue content.
10. The method according to claim 1 , wherein said overweight patient is a non-insulin-dependent diabetic human.